EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 191 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $513,000 | +43.7% | 6,777 | 0.0% | 0.79% | +92.4% |
Q1 2018 | $357,000 | -1.4% | 6,777 | 0.0% | 0.41% | -14.8% |
Q4 2017 | $362,000 | -10.4% | 6,777 | 0.0% | 0.48% | +18.8% |
Q3 2017 | $404,000 | -24.5% | 6,777 | -99.8% | 0.40% | -40.8% |
Q2 2017 | $535,000 | -99.8% | 3,652,284 | 0.0% | 0.68% | -99.2% |
Q1 2017 | $302,920,000 | -3.4% | 3,652,284 | -7.6% | 91.10% | +2.6% |
Q4 2016 | $313,558,000 | +2.2% | 3,952,078 | -9.8% | 88.77% | +5.0% |
Q3 2016 | $306,793,000 | +65.5% | 4,382,764 | -8.3% | 84.52% | +12.1% |
Q2 2016 | $185,423,000 | -4.2% | 4,780,188 | 0.0% | 75.43% | +0.3% |
Q1 2016 | $193,598,000 | -54.3% | 4,780,188 | 0.0% | 75.20% | -8.1% |
Q4 2015 | $423,859,000 | +19.8% | 4,780,188 | 0.0% | 81.80% | -2.3% |
Q3 2015 | $353,877,000 | -8.4% | 4,780,188 | 0.0% | 83.76% | +5.5% |
Q2 2015 | $386,526,000 | +93.0% | 4,780,188 | 0.0% | 79.39% | +21.5% |
Q1 2015 | $200,242,000 | +172.5% | 4,780,188 | +0.8% | 65.32% | +75.4% |
Q4 2014 | $73,488,000 | – | 4,741,187 | – | 37.25% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 112,666 | $1,777 | 0.65% |
Smith, Graham & Co., Investment Advisors, LP | 273,099 | $4,306,771 | 0.54% |
BRANDES INVESTMENT PARTNERS, LP | 1,134,363 | $17,888,904 | 0.35% |
TANG CAPITAL MANAGEMENT LLC | 118,857 | $1,874,375 | 0.26% |
Virtus Investment Advisers, Inc. | 20,867 | $329,073 | 0.22% |
DENALI ADVISORS LLC | 32,300 | $509,371 | 0.18% |
Nebula Research & Development LLC | 11,473 | $180,929 | 0.10% |
SCOUT INVESTMENTS, INC. | 131,192 | $1,995,430 | 0.05% |
XTX Topco Ltd | 15,050 | $237,339 | 0.04% |
PDT Partners, LLC | 19,745 | $311,379 | 0.04% |